Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for GlaxoSmithKline Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:
NSE:GLAXO'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.64 Med: 2.57 Max: 7.53
Current: 4.09
During the past 13 years, GlaxoSmithKline Pharmaceuticals's highest Yield on Cost was 7.53. The lowest was 1.64. And the median was 2.57.
NSE:GLAXO's 5-Year Yield-on-Cost % is ranked better than 67.84% of 513
companies
in the Drug Manufacturers industry
Industry Median: 2.29
vs NSE:GLAXO: 4.09
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
GlaxoSmithKline Pharmaceuticals 5-Year Yield-on-Cost % Related Terms
NSE:GLAXO vs LLY, JNJ, ABBV: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - General subindustry, GlaxoSmithKline Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Pharmaceuticals 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline Pharmaceuticals's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) has a 5-Year Yield-on-Cost % of 4.09 as of Jul. 20, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on GlaxoSmithKline Pharmaceuticals and its competitors. This is 59% above median its historical median of 2.57. Over the past decade, GlaxoSmithKline Pharmaceuticals' 5-Year Yield-on-Cost % has ranged from 1.64 to 7.53. According to the industry distribution chart, GlaxoSmithKline Pharmaceuticals ranks #165 out of 513 companies in the Drug Manufacturers industry, placing it in the top 32.2%.
Is GlaxoSmithKline Pharmaceuticals' 5-Year Yield-on-Cost % too high?
GlaxoSmithKline Pharmaceuticals' current 5-Year Yield-on-Cost % of 4.09 is 59% above median its 10-year median of 2.57. Over the past 10 years, this metric has ranged from a low of 1.64 to a high of 7.53. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.29. GlaxoSmithKline Pharmaceuticals' value of 4.09 is 78.6% above this industry median. Based on the distribution chart, GlaxoSmithKline Pharmaceuticals ranks #165 out of 513 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, GlaxoSmithKline Pharmaceuticals has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pharmaceuticals' 5-Year Yield-on-Cost % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GlaxoSmithKline Pharmaceuticals ranks #165 out of 513 companies for 5-Year Yield-on-Cost %. This puts GlaxoSmithKline Pharmaceuticals in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.29. GlaxoSmithKline Pharmaceuticals' value of 4.09 is 78.6% above this benchmark. Historically, GlaxoSmithKline Pharmaceuticals' own 5-Year Yield-on-Cost % has ranged from 1.64 to 7.53 over the past decade. While the company's 10-year median is 2.57 vs. the industry median of 2.29, GlaxoSmithKline Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.29, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GlaxoSmithKline Pharmaceuticals's current 5-Year Yield-on-Cost % of 4.09 is 78.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on GlaxoSmithKline Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline Pharmaceuticals's current 5-Year Yield-on-Cost % is 4.09, which is 59% above median its own 10-year median of 2.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,631.55, compared to a current price of ₹2,454.80 — trading 6.7% below its estimated fair value. The current 5-Year Yield-on-Cost % is 4.09, which is 59% above median its 10-year median of 2.57 and 78.6% above the Drug Manufacturers industry median of 2.29. GlaxoSmithKline Pharmaceuticals' overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For GlaxoSmithKline Pharmaceuticals (NSE:GLAXO), the current 5-Year Yield-on-Cost % is 4.09 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Overvalued in 2026?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹2,454.80 is trading 6.7% below its estimated GF Value™ of ₹2,631.55.
GuruFocus considers GlaxoSmithKline Pharmaceuticals to be Fairly Valued.
Key valuation signals for NSE:GLAXO:
5-Year Yield-on-Cost %: 4.09 (59% above median its 10-year median of 2.57)
GF Value™: ₹2,631.55 vs. price of ₹2,454.80 (6.7% below fair value)
Industry Position: 78.6% above the Drug Manufacturers median (#165 of 513)
No single metric tells the full story. See the NSE:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlaxoSmithKline Pharmaceuticals Business Description
GlaxoSmithKline Pharmaceuticals Ltd is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals. It is healthcare organisation focused on uniting science, technology and talent to get ahead of disease. The company's product portfolio comprises a broad range of General Medicines which includes anti-infectives, pain management, vitamins, minerals, nutritionals, hormones, dermatologicals, vaccines for both children and adults, and specialty medicines for respiratory and oncology. Its focused brands are Augmentin, Ceftum, Flutivate, T-bat, Betnovate, Neosporin, Tenovate, Physiogel, Calpol and Calpol T. The company has single reportable segment. The company has presence in India, and also Outside India. It generates majority of revenue from India.
73GF Score
Get the complete analysis for NSE:GLAXO
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLAXO has been successfully added to your 
